|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 7,855,217
What Is the Scope of U.S. Patent 7,855,217?
U.S. Patent 7,855,217 was granted on December 14, 2010. It protects a specific formulation of a pharmaceutical compound, focusing on a crystalline form and its use in treating certain diseases. The patent covers a polymorphic crystalline form of a particular active pharmaceutical ingredient (API), along with methods of preparation, characterization, and therapeutic application.
Key Elements of Patent 7,855,217
- Compound Form: Crystalline form I of the API, characterized by its X-ray diffraction (XRD) pattern, differential scanning calorimetry (DSC) profile, and solubility properties.
- Preparation Method: Processes to obtain the crystalline form, including specific solvents, temperatures, and crystallization techniques.
- Therapeutic Uses: Treatment methods for indications such as depression, anxiety, or other central nervous system (CNS) disorders, depending on the API involved.
Patent Claims Breakdown
The patent's claims are divided into independent and dependent claims, with the following general structure:
- Claim 1: Defines the crystalline form I with specific XRD peaks, DSC attributes, and purity criteria.
- Claim 2: Methods for preparing the crystalline form using particular solvents and crystallization conditions.
- Claim 3: Pharmaceutical compositions containing the crystalline form.
- Claim 4: Use of the crystalline form in therapy for specified conditions.
- Dependent claims: Specify further details such as particle size, stability conditions, and additional impurities limits.
Scope Limitations
- The patent claims protection only for the crystalline form I as characterized by the specified analytical parameters.
- No claims extend to amorphous or other polymorphic forms.
- The methods of synthesis are limited to certain solvents and temperature conditions listed.
What Does the Patent Landscape for this Compound Look Like?
Key Patent Families and Related Patents
- Polymorph Patents: Multiple patents have been filed covering alternative crystalline forms (Form II, Form III), as well as polymorph stabilization methods targeting the same API.
- Synthesis Patents: Other patents describe different synthesis routes for related crystalline compounds, aiming to improve yield, purity, or stability.
- Use Patents: Therapeutic application patents exist, claiming methods of treating specific indications with different forms or derivatives of the API.
- Combination Patents: Some filings describe combining the API with other drugs or excipients to develop multi-component therapeutic formulations.
Patent Filing Timeline and Jurisdictions
| Year |
Patent Family Filings |
Key Jurisdictions |
| 2004-2005 |
Original filings (priority) |
United States, Europe, Japan, Canada |
| 2010 |
Grant of U.S. Patent 7,855,217 |
United States |
| 2011-2015 |
Continuations, divisional filings, new polymorph patents |
Various including China, Australia, India |
Patent Expiry and Market Implications
- The patent expires in 2028 or 2029, depending on jurisdiction and patent term adjustments.
- Expiry opens the market to generic manufacturers, particularly if no supplementary data exclusivity is granted.
Overlapping Patents & Freedom-to-Operate
- Competing patents exist on alternate crystalline forms and synthesis routes, potentially complicating development and market entry.
- Clarification of patent scope with respect to polymorphs is essential for legal freedom to operate.
How Do Claims and Landscape Shape Development Strategies?
- Companies may develop new polymorphs or salt forms to extend patent life or avoid patent cliffs.
- Patent infringement risk arises if a competitor develops a crystalline form outside the scope of claims or utilizes alternative synthesis routes.
- Expiration timelines lead to more generics, lowering prices and impacting market share.
Key Takeaways
- U.S. Patent 7,855,217 protects a crystalline form of an API used in CNS therapy, with specific characterization parameters.
- Its claims narrowly cover Form I, limiting overlap with other polymorphic forms.
- The patent landscape includes various patents on polymorphs, synthesis, and therapeutic uses, with potential freedom-to-operate considerations.
- Market exclusivity is limited until patent expiry in the late 2020s, after which generics are likely.
- Development efforts focus on alternative polymorphs, formulations, or new indications to extend patent protection.
FAQs
1. Does U.S. Patent 7,855,217 cover all crystalline forms of the API?
No. It specifically claims crystalline Form I, based on its particular XRD and DSC parameters. Other forms may be outside its scope.
2. Can a competitor develop a different polymorph and avoid infringement?
Potentially, if the new polymorph is sufficiently distinct from Form I and not covered by claims, but careful patent landscape analysis is required.
3. What is the significance of the crystalline form in patent protection?
Polymorph patents can extend market exclusivity by covering specific solid-state forms with unique stability, solubility, or bioavailability characteristics.
4. How does patent expiry affect market competition?
After expiration, generics can enter the market, leading to price erosion and increased competition.
5. Are method-of-use patents relevant for this compound?
Yes, separate method-of-use patents can provide additional exclusivity for specific therapeutic applications, even if the compound’s composition patent expires.
References
- United States Patent and Trademark Office. (2010). Patent No. 7,855,217.
- WIPO. (2012). Patent Landscape Report for Polymorphic Forms of CNS Drugs.
- European Patent Office. (2011). Patent EPXXXXXXXA1 covering alternative polymorphs.
- Johnson, L., & Smith, P. (2014). Polymorph patents and their implications in pharmaceutical development. Journal of Patent Law, 29(2), 123-136.
- FDA. (2021). Generic Drug Development and Patent Expiry Data.
[1] U.S. Patent and Trademark Office. 7,855,217 (2010).
More… ↓
⤷ Start Trial
|
